

BIOCON GROUP

Q4 FY 2009 vs Q4 FY 2008

AND

YTD MAR FY 09 VS YTD MAR FY 08

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		<i>(Rs. Millions)</i>
Particulars	As at 31-Mar-09	As at 31-Mar-08
<u>SOURCES OF FUNDS</u>		
Share Capital	1,000	500
Reserves & Surplus	14,194	14,341
Total Shareholder's Funds	15,194	14,841
Minority interest	227	-73
Deferred Tax Liability	466	465
Secured Loans	3,983	1,351
Unsecured Loans	1,275	1,200
Total Loan Funds	5,258	2,551
Total	21,145	17,784
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	13,345	10,419
Intangible Assets	499	276
Investments	3,676	4,748
Inventories	3,192	1,790
Sundry debtors	3,671	2,591
Cash and bank balances	119	96
Loans and advances	1,015	869
Total Current Assets, Loans & Advances	7,997	5,346
Less: Current liabilities and provisions	4,372	3,005
Net Current assets	3,625	2,341
Total	21,145	17,784

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Millions)

(Rs. Millions)

Particulars	Q4	Q4	Q4	Variance Without Axicorp	Full Year ended Mar 31, 2009	Full Year ended Mar 31, 2009	Full Year ended March 31, 2008	Variance Without Axicorp
	With Axicorp FY 2009	Without Axicorp FY 2009	FY 2008		With Axicorp	Without Axicorp	2008	
INCOME								
Biopharmaceuticals*	3,984	2,242	2,205	2%	13,841	9,147	8,323	10%
Contract research	679	679	461	47%	2,246	2,246	1,755	28%
	4,663	2,921	2,666	10%	16,087	11,393	10,078	13%
Enzymes	-	-	-	-	-	-	460	-
Total Sales	4,663	2,921	2,666	10%	16,087	11,393	10,538	8%
Other income	203	123	126	-2%	646	544	364	49%
Total Income / Revenues	4,866	3,044	2,792	9%	16,733	11,937	10,902	9%
EXPENDITURE								
Material & Power Costs	2,790	1,310	1,293	1%	9,078	5,161	5,116	1%
Staff costs	448	317	217	46%	1,653	1,291	1,002	29%
Research & Development	202	202	141	43%	598	598	471	27%
Forex Loss/ (gain)	(48)	(51)	(12)	325%	112	105	(23)	-557%
Other Expenses	372	250	201	24%	1,412	1,067	986	8%
Manufacturing, staff & other exps	3,764	2,028	1,840	9%	12,853	8,222	7,552	
PBDIT /EBIDTA	1,102	1,016	952	6%	3,880	3,715	3,350	10%
Interest and finance charges	62	52	28	85%	177	154	102	
PBDT	1,040	964	924	2%	3,703	3,561	3,248	8%
Depreciation	307	296	242	21%	1,103	1,077	939	
PBT	733	668	682	-5%	2,600	2,484	2,309	5%
Taxes	(16)	(15)	60	-126%	118	101	129	
PROFIT FOR THE PERIOD	749	683	622	10%	2,482	2,383	2,180	9%
Add/(less): Minority interest / Share of Losses in Associates	(86)	(66)	22		(79)	(45)	65	
Profit before Exceptional Items	663	617	644	-4%	2,403	2,338	2,245	4%
Exceptional Item - Net of Tax **	(414)	(414)	9		(1472)	(1472)	2,394	
NET PROFIT (PAT)	249	203	653	-69%	931	866	4,639	-81%
EPS on issued capital Rs. (before exceptional items)	3.3	3.1			12.0	11.7	22.5	

Note: The figures are rounded off to nearest million, percentages are based on absolute numbers

* Includes Technical licensing fee Rs.64 (Q4 FY 09), Rs. 103 (Q4 FY 08), Rs. 123 (FY 09) and Rs.448 (FY 08)

** Exceptional item for the year ended March 31, 2009 comprise MTM loss in respect of forex forward contracts

** Exceptional item for the year March 31, 2008 comprise Profit on Divestment of Enzyme